Lung Cancer

Efficacy findings from the phase 1/2 LIBRETTO-001 and LIBRETTO-021 trials supported the regulatory approval of selpercatinib in RET gene fusion-positive solid tumors.

The RASolute 302 study of daraxonrasib was “the single biggest study presentation” at ASCO 2026, according to Sivraj Muralikrishnan, MD.

The FLAME trial showed osimertinib plus carboplatin/pemetrexed significantly improved PFS vs osimertinib monotherapy in ctDNA-persistent EGFR-mutant NSCLC.

The phase 3 HARMONi-6 trial showed ivonescimab plus chemotherapy significantly improved OS vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

About 50% to 60% of Lambert-Eaton myasthenic syndrome cases occur secondary to a malignancy, most commonly small cell lung cancer, and 3% of patients with SCLC have LEMS.

Data from the Lung-Care Project showed that non–high-risk patients experienced better survival and curative potential through early detection.

According to Brian Henick, MD, understanding why certain patients experience specific AEs will be key for giving more precise lung cancer therapy.

The FDA approved zongertinib in HER2-mutated NSCLC as part of its Commissioner's National Priority Voucher pilot program.

Read this discussion to spot LEMS red flags tied to small cell lung cancer, avoid misdiagnosis, and follow antibody/EMG testing and screening steps.

Olvimulogene nanivacirepvec yielded 3 partial responses among 9 evaluable patients with SCLC who had progression or recurrence on prior therapy.

OncoPrism-NSCLC was found to be a predictive biomarker of immune checkpoint inhibitor benefit vs a general prognostic tool in patients with NSCLC.

Expert teams debate cutting-edge lung cancer treatments, exploring trial data and innovative strategies for improving patient outcomes in NSCLC and SCLC.

With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.

An oncologist at the Georgia Cancer Center discussed the evolution of treatment strategies and emerging therapies for patients with EGFR-mutated disease.

Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.

Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.

Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.

The blood-based test detected 31% of lung cancers one year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.

Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.

Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.

Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.

Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.

Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.